These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11401666)

  • 1. S100A6 expression in fibrohistiocytic lesions.
    Fullen DR; Reed JA; Finnerty B; McNutt NS
    J Cutan Pathol; 2001 May; 28(5):229-34. PubMed ID: 11401666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
    West KL; Cardona DM; Su Z; Puri PK
    Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
    Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
    Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
    Li N; McNiff J; Hui P; Manfioletti G; Tallini G
    Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
    Kahn HJ; Fekete E; From L
    Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
    Lee CS; Chou ST
    Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
    Franchi A; Santucci M
    Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A6 preferentially labels type C nevus cells and nevic corpuscles: additional support for Schwannian differentiation of intradermal nevi.
    Fullen DR; Reed JA; Finnerty B; McNutt NS
    J Cutan Pathol; 2001 Sep; 28(8):393-9. PubMed ID: 11493376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of S100A6 protein in a broad spectrum of cutaneous tumors using tissue microarrays.
    Fullen DR; Garrisi AJ; Sanders D; Thomas D
    J Cutan Pathol; 2008 Nov; 35 Suppl 2():28-34. PubMed ID: 18201235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
    Taniuchi K; Yamada Y; Nonomura A; Takehara K
    J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
    Goldblum JR; Tuthill RJ
    Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ.
    King R; Googe PB; Page RN; Mihm MC
    Mod Pathol; 2005 Aug; 18(8):1043-7. PubMed ID: 15803191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unique biphasic variant of cutaneous fibrous histiocytoma with a storiform pattern and intralesional pigmented melanocytes: "storiform melano-fibrous histiocytoma".
    Nair V; Weinreb I; MacNeil N; Szollosi Z; Chetty R; Ghazarian D
    Eur J Dermatol; 2008; 18(3):332-6. PubMed ID: 18474466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
    Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
    Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
    Abenoza P; Lillemoe T
    Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. nm23 protein expression and p53 immunoreactivity in cutaneous fibrohistiocytic tumors.
    Lee CS; Clarke RA; Tran KT; Kearsley JH; Chou ST
    Pathology; 1999 May; 31(2):123-6. PubMed ID: 10399167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrohistiocytic Tumors.
    Romano RC; Fritchie KJ
    Clin Lab Med; 2017 Sep; 37(3):603-631. PubMed ID: 28802503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular digital fibromas: distinctive CD34-positive lesions that may mimic dermatofibrosarcoma protuberans.
    McNiff JM; Subtil A; Cowper SE; Lazova R; Glusac EJ
    J Cutan Pathol; 2005 Jul; 32(6):413-8. PubMed ID: 15953374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
    Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
    Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.